NEXGEL Inc (NXGL) Price to Earnings Ratio

Localizing capacities in the US eliminates geopolitical risks and trade restrictions for NEXGEL, Inc. (NXGL). Operational efficiency is maintained by outsourcing a portion of production and logistics to external partners. The current P/E ratio is -0.30. The price action of the securities confirms the brand status of a company trusted by medical professionals for its innovative hydrogel systems for tissue regeneration and wound healing.

NEXGEL (NXGL) - P/E Multiple from 07/04/2022 to 11/12/2026

Analytical breakdowns for NEXGEL, Inc.

- price and consensus price forecast:

Stock Price nexgel.com|NXGL - Price Target Chart

- market capitalization details:

Market Value NEXGEL, Inc.|NXGL - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value of a Share NEXGEL|NXGL - Book Capitalization|Market Capitalization to Book Value nexgel.com|NXGL - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples indicators:

NXGL - Company Net Income|Future Profit NEXGEL, Inc.|NXGL - P/E Multiple|Projected Price to Earnings Ratio NEXGEL Inc.|NXGL - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation NEXGEL, Inc.|NXGL - Operating profit before deduction of amortization|Earnings per share for the last four quarters NEXGEL|NXGL - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months nexgel.com|NXGL - Earnings per share growth in current year|Projected earnings per share growth rate for next year NEXGEL, Inc.

General company analysis:nexgel.com, NXGL

The P/E ratio determines the cost per unit of profit, allowing an investor to assess the premium paid for an asset and its resilience to market shocks. By analyzing the P/E time series of NEXGEL, Inc. (NXGL), one can compare the market value of NEXGEL, Inc. (NXGL) with predictable revenues from regular medical hydrogel supplies, which helps differentiate a fair business valuation from speculative risk given the high repeatability of sales.

Analysis of competing companies